K. Katariina Helena Erkkilä

Part of Midaxo Oy, Midaxo, Inc. is a corporate dealmaking software platform that offers a purpose-built M&A pipeline management platform. The company is based in Boston, MA, and the CEO of the company is Jude McColgan. The platform helps to source 5x more deals, reduce costs and inefficiencies, and eliminate divestment strategy challenges with Midaxo playbooks, communication tools, and live reporting. The company has powered more than 5,000 transactions valued at over $1T and has been used by over 500 companies across a broad range of industries. Midaxo's cloud-based M&A software platform is trusted by top-tier consulting, M&A advisory, and private equity firms to unlock value for their clients and portfolio companies.

Iris Molecular Diagnostics, Inc. operates as a bio-technology company. The company was founded on April 18, 2006 and is headquartered in Chatsworth. CA.

Part of Midaxo Oy, Midaxo, Inc. is a corporate dealmaking software platform that offers a purpose-built M&A pipeline management platform. The company is based in Boston, MA, and the CEO of the company is Jude McColgan. The platform helps to source 5x more deals, reduce costs and inefficiencies, and eliminate divestment strategy challenges with Midaxo playbooks, communication tools, and live reporting. The company has powered more than 5,000 transactions valued at over $1T and has been used by over 500 companies across a broad range of industries. Midaxo's cloud-based M&A software platform is trusted by top-tier consulting, M&A advisory, and private equity firms to unlock value for their clients and portfolio companies.